Related Experiment Videos

Cardiomyopathy and changes of skeletal muscles in cystic fibrosis

V Herout1, D Benesová, V Vávrová

  • 1Faculty of Medicine, Charles University, Hradec Králové, Czechoslovakia.

Acta Universitatis Carolinae. Medica
|January 1, 1990
PubMed

Insights

Cardiomyopathy (CMP) is a serious concern in children with cystic fibrosis (CF). Early suspicion of CMP in CF patients with heart failure is crucial for timely diagnosis and intervention.

Area of Science:

  • Pediatrics
  • Cardiology
  • Genetics

Background:

  • Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
  • Cardiomyopathy (CMP) is a known but under-recognized complication in CF.
  • The interplay between CF and cardiac muscle dysfunction requires further investigation.

Purpose of the Study:

  • To investigate the incidence and outcomes of cardiomyopathy in pediatric cystic fibrosis patients.
  • To highlight the association between cardiomyopathy and sudden death in CF.
  • To report the concurrent presentation of skeletal and cardiac muscle abnormalities in CF.

Main Methods:

  • Retrospective analysis of pediatric patients diagnosed with cystic fibrosis.
  • Review of clinical records for diagnosis of cardiomyopathy and heart failure.
  • Correlation of cardiomyopathy with mortality and age at death.

Main Results:

  • Cardiomyopathy was identified in 26 children with cystic fibrosis.
  • A high mortality rate (92%) was observed in these patients, with most deaths occurring before age 3.
  • The study identified a novel combination of skeletal and cardiac muscle changes in CF.

Conclusions:

  • Cardiomyopathy should be suspected in young children with CF presenting with heart failure.
  • Cardiomyopathy is a significant cause of mortality in pediatric CF, particularly in early childhood.
  • This study is the first to report combined skeletal and cardiac muscle pathology in CF.

Related Concept Videos